SCT-I10A + cisplatin + 5-fluorouracil

SCT-I10A + cisplatin + 5-fluorouracil** is an experimental combination regimen primarily explored for treatment of advanced or refractory solid tumors, especially colorectal and head and neck cancers. SCT-I10A is a recombinant humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor. Cisplatin and 5-fluorouracil are established cytotoxic chemotherapies: cisplatin is a platinum-containing DNA crosslinker causing apoptosis, while 5-fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, interrupting DNA synthesis. SCT-I10A, acting as an anti-PD-1 antibody, enhances T-cell mediated antitumor immunity. In published studies and ongoing clinical trials, SCT-I10A is typically combined with chemotherapy—including platinum-based agents and 5-fluorouracil—in refractory cancers to boost antitumor efficacy by combining immune checkpoint inhibition with direct cytotoxic effects[1][2][3][4].

Other names

finotonlimab + C5Ffinotonlimab + cisplatin + 5-fluorouracil